The phenotype of newly diagnosed Graves' disease in Italy in recent years is milder than in the past: results of a large observational longitudinal study

被引:46
作者
Bartalena, L. [1 ]
Masiello, E. [1 ]
Magri, F. [2 ,3 ]
Veronesi, G. [1 ,4 ]
Bianconi, E. [1 ]
Zerbini, F. [2 ,3 ]
Gaiti, M. [2 ,3 ]
Spreafico, E. [1 ]
Gallo, D. [1 ]
Premoli, P. [1 ]
Piantanida, E. [1 ]
Tanda, M. L. [1 ]
Ferrario, M. [1 ,4 ]
Vitti, P. [5 ]
Chiovato, L. [2 ,3 ]
机构
[1] Univ Insubria, Dept Clin & Expt Med, Endocrine Unit, ASST Sette Laghi, Viale Borri 57, I-21100 Varese, Italy
[2] Univ Pavia, Salvatore Maugeri Fdn, Pavia, Italy
[3] Univ Pavia, Dept Internal Med & Med Therapy, Pavia, Italy
[4] Univ Insubria, Res Ctr Epidemiol & Prevent Med EPIMED, Varese, Italy
[5] Univ Pisa, Dept Clin & Expt Med, Pisa, Italy
关键词
Graves' disease; Hyperthyroidism; Graves' orbitopathy; Antithyroid drugs; Thyrotropin receptor antibody; Goiter; RECEPTOR ANTIBODIES; NATURAL-HISTORY; THYROID GROWTH; HYPERTHYROIDISM; ORBITOPATHY; OPHTHALMOPATHY; PREVALENCE; MANAGEMENT; SMOKING; GOITER;
D O I
10.1007/s40618-016-0516-7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The Merseburg triad (hyperthyroidism, goiter, and orbitopathy) characterizes classical description of Graves' disease (GD). Aim of this observational, longitudinal study was to evaluate the current clinical features of newly diagnosed GD in Italy. In two Northern Italy centers (Varese and Pavia), 283 consecutive patients (211 women, 72 men; mean age 47.4 years) with newly diagnosed GD were recruited in the years 2010-2014. Diagnosis was based on established criteria, and thyroid volume was assessed by ultrasonography. A clinical severity score (CSS) to assess the overall disease severity was developed by grading each component of the Merseburg triad. At diagnosis, 45 % of patients had no goiter, and 30 % had a small goiter. The proportion of goitrous patients was much lower than in two Italian studies performed 20-30 years ago. Hyperthyroidism was subclinical in 16 % and mild in 29 % of patients, and Graves' orbitopathy was present in 20 %, usually mild, and active in only 2.5 % of patients. Using the CSS, less than half (44 %) of the patients had severe GD, while 22 % had mild and 34 % moderate disease. CSS was associated with a significantly higher risk of poorly controlled hyperthyroidism at 6 months. In Italy, a relevant proportion of Graves' patients at diagnosis have mild to moderate GD; about half of them have no goiter, slightly less than one-fifth have subclinical hyperthyroidism, and only 20 % have GO. Thus, the clinical phenotype of GD is milder than in the past, possibly due to both earlier diagnosis and treatment, and improved iodine nutrition.
引用
收藏
页码:1445 / 1451
页数:7
相关论文
共 27 条
[1]   IODIZED SALT PROPHYLAXIS OF ENDEMIC GOITER - AN EXPERIENCE IN TOSCANA (ITALY) [J].
AGHINILOMBARDI, F ;
PINCHERA, A ;
ANTONANGELI, L ;
RAGO, T ;
FENZI, GF ;
NANNI, P ;
VITTI, P .
ACTA ENDOCRINOLOGICA, 1993, 129 (06) :497-500
[2]   Clinical Utility of TSH Receptor Antibodies [J].
Barbesino, Giuseppe ;
Tomer, Yaron .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2013, 98 (06) :2247-2255
[3]   Effects of treatment modalities for Graves' hyperthyroidism on Graves' orbitopathy: a 2015 Italian Society of Endocrinology Consensus Statement [J].
Bartalena, L. ;
Macchia, P. E. ;
Marcocci, C. ;
Salvi, M. ;
Vermiglio, F. .
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2015, 38 (04) :481-487
[4]   Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO [J].
Bartalena, Luigi ;
Baldeschi, Lelio ;
Dickinson, Alison ;
Eckstein, Anja ;
Kendall-Taylor, Pat ;
Marcocci, Claudio ;
Mourits, Maarten ;
Perros, Petros ;
Boboridis, Kostas ;
Boschi, Antonella ;
Curro, Nicola ;
Daumerie, Chantal ;
Kahaly, George J. ;
Krassas, Gerasimos E. ;
Lane, Carol M. ;
Lazarus, John H. ;
Marino, Michele ;
Nardi, Marco ;
Neoh, Christopher ;
Orgiazzi, Jacques ;
Pearce, Simon ;
Pinchera, Aldo ;
Pitz, Susanne ;
Salvi, Mario ;
Sivelli, Paolo ;
Stahl, Matthias ;
von Arx, Georg ;
Wiersinga, Wilmar M. .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2008, 158 (03) :273-285
[5]   Extrathyroidal manifestations of Graves' disease: a 2014 update [J].
Bartalena, Luigi ;
Fatourechi, Vahab .
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2014, 37 (08) :691-700
[6]   Diagnosis and management of Graves disease: a global overview [J].
Bartalena, Luigi .
NATURE REVIEWS ENDOCRINOLOGY, 2013, 9 (12) :724-734
[7]   Graves' disease [J].
Brent, Gregory A. .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (24) :2594-2605
[8]   Prognostic value of thyrotropin receptor antibodies (TRAb) in Graves' disease: A 120 months prospective study [J].
Cappelli, Carlo ;
Gandossi, Elena ;
Castellano, Maurizio ;
Pizzocaro, Claudio ;
Agosti, Barbara ;
Delbarba, Andrea ;
Pirola, Ilenia ;
De Martino, Elvira ;
Rosei, Enrico Agabiti .
ENDOCRINE JOURNAL, 2007, 54 (05) :713-720
[9]   DETECTION OF THYROID GROWTH IMMUNOGLOBULINS (TGI) BY [THYMIDINE-H-3 INCORPORATION IN CULTURED RAT-THYROID FOLLICLES [J].
CHIOVATO, L ;
HAMMOND, LJ ;
HANAFUSA, T ;
PUJOLBORRELL, R ;
DONIACH, D ;
BOTTAZZO, GF .
CLINICAL ENDOCRINOLOGY, 1983, 19 (05) :581-590
[10]   Effects of L-thyroxine administration, TSH-receptor antibodies and smoking on the risk of recurrence in Graves' hyperthyroidism treated with antithyroid drugs: a double-blind prospective randomized study [J].
Glinoer, D ;
de Nayer, P ;
Bex, M .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2001, 144 (05) :475-483